Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) and Prime Medicine (NYSE:PRME – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Insider & Institutional Ownership
21.0% of Finch Therapeutics Group shares are owned by institutional investors. 44.6% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Finch Therapeutics Group and Prime Medicine’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Finch Therapeutics Group||-6,431.16%||-52.79%||-41.29%|
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Finch Therapeutics Group||0||0||2||0||3.00|
Finch Therapeutics Group presently has a consensus target price of $17.00, indicating a potential upside of 4,373.68%. Given Finch Therapeutics Group’s higher possible upside, research analysts plainly believe Finch Therapeutics Group is more favorable than Prime Medicine.
Earnings & Valuation
This table compares Finch Therapeutics Group and Prime Medicine’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Finch Therapeutics Group||$18.53 million||0.98||-$58.16 million||($2.25)||-0.17|
|Prime Medicine||$5.21 million||229.41||-$121.82 million||N/A||N/A|
Finch Therapeutics Group has higher revenue and earnings than Prime Medicine.
Finch Therapeutics Group beats Prime Medicine on 6 of the 10 factors compared between the two stocks.
About Finch Therapeutics Group
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
About Prime Medicine
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.